Doufas, Anthony G.
Laporta, Mariana L.
Driver, C. Noelle
Di Piazza, Fabio
Scardapane, Marco
Bergese, Sergio D.
Urman, Richard D.
Khanna, Ashish K.
Weingarten, Toby N.
Jungquist, Carla R.
Morimatsu, Hiroshi
Uezono, Shoichi
Lee, Simon
Ti, Lian Kah
McIntyre, Robert Jr
Tornero, Carlos
Dahan, Albert
Saager, Leif
Wittmann, Maria
Auckley, Dennis
Brazzi, Luca
Le Guen, Morgan
Soto, Roy
Schramm, Frank
Buhre, Wolfgang
Overdyk, Frank J.
,
Funding for this research was provided by:
Medtronic
Article History
Received: 20 June 2023
Accepted: 22 September 2023
First Online: 4 October 2023
Declarations
:
: Ethics approval was collected for each trial site (Partners Human Research Committee, Protocol # 2017P000196/PHS, Brigham & Women’s Hospital, Boston, MA and Western Institutional Review Board, Protocol # COVMO0560-PRODIGY, The Ohio State University Wexner Medical Center, Columbus, OH). Written informed consent was required before a patient was enrolled in the trial. All methods were carried out in accordance with relevant guidelines and regulations (Declaration of Helsinki).
: Not applicable.
: TNW, AKK, SDB, and RDU or their institutions received financial support from Medtronic to fund the original trial. In addition, TNW reports personal fees from Merck; RDU reports funding and/or personal fees from Merck, Medtronic, AcelRx, and Pfizer; AKK reports consulting fees from Medtronic, Edwards Lifesciences, Philips Research North America, GE Healthcare, Baxter, Retia Medical, Caretaker Medical, Trevena Pharmaceuticals, Renibus Therapeutics and support via an NIH/NCATS KL2 award for a trial of continuous portable monitoring on hospital general care floors. FDP and MS report full time employment with Medtronic during the time of the work. MLL, CND, and AGD declare that they have no competing interests.